Intrinsic value of ICU Medical - ICUI

Previous Close

$264.70

  Intrinsic Value

$133.01

stock screener

  Rating & Target

sell

-50%

Previous close

$264.70

 
Intrinsic value

$133.01

 
Up/down potential

-50%

 
Rating

sell

We calculate the intrinsic value of ICUI stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 5.4

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  8.70
  8.33
  8.00
  7.70
  7.43
  7.18
  6.97
  6.77
  6.59
  6.43
  6.29
  6.16
  6.04
  5.94
  5.85
  5.76
  5.69
  5.62
  5.56
  5.50
  5.45
  5.40
  5.36
  5.33
  5.30
  5.27
  5.24
  5.22
  5.19
  5.17
Revenue, $m
  1,405
  1,522
  1,644
  1,770
  1,902
  2,039
  2,181
  2,328
  2,482
  2,641
  2,807
  2,980
  3,161
  3,348
  3,544
  3,748
  3,961
  4,184
  4,416
  4,659
  4,913
  5,179
  5,456
  5,747
  6,051
  6,370
  6,704
  7,053
  7,420
  7,804
Variable operating expenses, $m
  1,096
  1,186
  1,280
  1,377
  1,478
  1,583
  1,692
  1,806
  1,924
  2,047
  2,159
  2,292
  2,430
  2,575
  2,725
  2,882
  3,046
  3,217
  3,396
  3,583
  3,778
  3,982
  4,196
  4,419
  4,653
  4,898
  5,155
  5,424
  5,705
  6,000
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  1,096
  1,186
  1,280
  1,377
  1,478
  1,583
  1,692
  1,806
  1,924
  2,047
  2,159
  2,292
  2,430
  2,575
  2,725
  2,882
  3,046
  3,217
  3,396
  3,583
  3,778
  3,982
  4,196
  4,419
  4,653
  4,898
  5,155
  5,424
  5,705
  6,000
Operating income, $m
  309
  336
  364
  393
  424
  455
  488
  522
  558
  595
  649
  689
  730
  774
  819
  866
  915
  967
  1,021
  1,077
  1,135
  1,197
  1,261
  1,328
  1,398
  1,472
  1,549
  1,630
  1,715
  1,803
EBITDA, $m
  387
  420
  453
  488
  524
  562
  601
  642
  684
  728
  774
  822
  871
  923
  977
  1,033
  1,092
  1,153
  1,217
  1,284
  1,354
  1,428
  1,504
  1,584
  1,668
  1,756
  1,848
  1,944
  2,045
  2,151
Interest expense (income), $m
  0
  0
  1
  3
  4
  6
  8
  9
  11
  13
  15
  17
  19
  21
  23
  26
  28
  31
  33
  36
  39
  42
  45
  48
  52
  55
  59
  63
  67
  72
  76
Earnings before tax, $m
  309
  335
  361
  389
  418
  448
  479
  511
  545
  580
  632
  670
  709
  750
  793
  838
  885
  934
  985
  1,038
  1,093
  1,152
  1,212
  1,276
  1,343
  1,413
  1,486
  1,563
  1,643
  1,727
Tax expense, $m
  83
  90
  98
  105
  113
  121
  129
  138
  147
  157
  171
  181
  192
  203
  214
  226
  239
  252
  266
  280
  295
  311
  327
  345
  363
  381
  401
  422
  444
  466
Net income, $m
  226
  244
  264
  284
  305
  327
  350
  373
  398
  423
  461
  489
  518
  548
  579
  612
  646
  682
  719
  758
  798
  841
  885
  932
  980
  1,031
  1,085
  1,141
  1,199
  1,261

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,529
  1,656
  1,789
  1,926
  2,069
  2,218
  2,373
  2,533
  2,700
  2,874
  3,055
  3,243
  3,439
  3,643
  3,856
  4,079
  4,311
  4,553
  4,806
  5,070
  5,346
  5,635
  5,937
  6,254
  6,585
  6,932
  7,295
  7,675
  8,074
  8,492
Adjusted assets (=assets-cash), $m
  1,529
  1,656
  1,789
  1,926
  2,069
  2,218
  2,373
  2,533
  2,700
  2,874
  3,055
  3,243
  3,439
  3,643
  3,856
  4,079
  4,311
  4,553
  4,806
  5,070
  5,346
  5,635
  5,937
  6,254
  6,585
  6,932
  7,295
  7,675
  8,074
  8,492
Revenue / Adjusted assets
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
  0.919
Average production assets, $m
  313
  339
  367
  395
  424
  455
  486
  519
  553
  589
  626
  665
  705
  747
  790
  836
  883
  933
  985
  1,039
  1,096
  1,155
  1,217
  1,282
  1,349
  1,421
  1,495
  1,573
  1,655
  1,740
Working capital, $m
  385
  417
  450
  485
  521
  559
  597
  638
  680
  724
  769
  817
  866
  917
  971
  1,027
  1,085
  1,146
  1,210
  1,277
  1,346
  1,419
  1,495
  1,575
  1,658
  1,745
  1,837
  1,933
  2,033
  2,138
Total debt, $m
  25
  52
  81
  110
  140
  172
  204
  238
  274
  311
  349
  389
  430
  474
  519
  566
  615
  666
  720
  776
  835
  896
  960
  1,027
  1,097
  1,171
  1,248
  1,328
  1,413
  1,502
Total liabilities, $m
  324
  351
  379
  408
  439
  470
  503
  537
  572
  609
  648
  688
  729
  772
  818
  865
  914
  965
  1,019
  1,075
  1,133
  1,195
  1,259
  1,326
  1,396
  1,469
  1,546
  1,627
  1,712
  1,800
Total equity, $m
  1,205
  1,305
  1,410
  1,518
  1,631
  1,748
  1,870
  1,996
  2,128
  2,265
  2,407
  2,556
  2,710
  2,871
  3,039
  3,214
  3,397
  3,587
  3,787
  3,995
  4,213
  4,440
  4,679
  4,928
  5,189
  5,462
  5,748
  6,048
  6,362
  6,691
Total liabilities and equity, $m
  1,529
  1,656
  1,789
  1,926
  2,070
  2,218
  2,373
  2,533
  2,700
  2,874
  3,055
  3,244
  3,439
  3,643
  3,857
  4,079
  4,311
  4,552
  4,806
  5,070
  5,346
  5,635
  5,938
  6,254
  6,585
  6,931
  7,294
  7,675
  8,074
  8,491
Debt-to-equity ratio
  0.020
  0.040
  0.060
  0.070
  0.090
  0.100
  0.110
  0.120
  0.130
  0.140
  0.140
  0.150
  0.160
  0.160
  0.170
  0.180
  0.180
  0.190
  0.190
  0.190
  0.200
  0.200
  0.210
  0.210
  0.210
  0.210
  0.220
  0.220
  0.220
  0.220
Adjusted equity ratio
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788
  0.788

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  226
  244
  264
  284
  305
  327
  350
  373
  398
  423
  461
  489
  518
  548
  579
  612
  646
  682
  719
  758
  798
  841
  885
  932
  980
  1,031
  1,085
  1,141
  1,199
  1,261
Depreciation, amort., depletion, $m
  78
  83
  89
  95
  100
  107
  113
  119
  126
  133
  125
  133
  141
  149
  158
  167
  177
  187
  197
  208
  219
  231
  243
  256
  270
  284
  299
  315
  331
  348
Funds from operations, $m
  304
  328
  353
  379
  406
  433
  463
  493
  524
  557
  587
  622
  659
  697
  737
  779
  823
  868
  916
  965
  1,017
  1,072
  1,128
  1,188
  1,250
  1,315
  1,384
  1,455
  1,530
  1,609
Change in working capital, $m
  31
  32
  33
  35
  36
  37
  39
  40
  42
  44
  46
  47
  49
  51
  54
  56
  58
  61
  64
  67
  70
  73
  76
  80
  83
  87
  91
  96
  100
  105
Cash from operations, $m
  273
  296
  319
  344
  370
  396
  424
  452
  482
  513
  541
  575
  609
  646
  684
  723
  764
  807
  852
  899
  948
  999
  1,052
  1,108
  1,167
  1,228
  1,292
  1,359
  1,430
  1,504
Maintenance CAPEX, $m
  -58
  -63
  -68
  -73
  -79
  -85
  -91
  -97
  -104
  -111
  -118
  -125
  -133
  -141
  -149
  -158
  -167
  -177
  -187
  -197
  -208
  -219
  -231
  -243
  -256
  -270
  -284
  -299
  -315
  -331
New CAPEX, $m
  -25
  -26
  -27
  -28
  -29
  -30
  -32
  -33
  -34
  -36
  -37
  -39
  -40
  -42
  -44
  -46
  -48
  -50
  -52
  -54
  -57
  -59
  -62
  -65
  -68
  -71
  -74
  -78
  -82
  -86
Cash from investing activities, $m
  -83
  -89
  -95
  -101
  -108
  -115
  -123
  -130
  -138
  -147
  -155
  -164
  -173
  -183
  -193
  -204
  -215
  -227
  -239
  -251
  -265
  -278
  -293
  -308
  -324
  -341
  -358
  -377
  -397
  -417
Free cash flow, $m
  190
  207
  224
  242
  261
  281
  301
  322
  344
  367
  386
  411
  436
  463
  491
  519
  550
  581
  614
  648
  683
  721
  759
  800
  843
  887
  934
  982
  1,034
  1,087
Issuance/(repayment) of debt, $m
  25
  27
  28
  29
  30
  32
  33
  34
  35
  37
  38
  40
  42
  43
  45
  47
  49
  51
  54
  56
  59
  61
  64
  67
  70
  74
  77
  81
  85
  89
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  25
  27
  28
  29
  30
  32
  33
  34
  35
  37
  38
  40
  42
  43
  45
  47
  49
  51
  54
  56
  59
  61
  64
  67
  70
  74
  77
  81
  85
  89
Total cash flow (excl. dividends), $m
  216
  234
  252
  272
  292
  312
  334
  356
  379
  404
  424
  451
  478
  506
  536
  567
  599
  632
  667
  704
  742
  782
  824
  867
  913
  961
  1,011
  1,063
  1,118
  1,176
Retained Cash Flow (-), $m
  -96
  -100
  -104
  -108
  -113
  -117
  -122
  -127
  -132
  -137
  -142
  -148
  -154
  -161
  -168
  -175
  -183
  -191
  -199
  -208
  -218
  -228
  -238
  -249
  -261
  -273
  -286
  -300
  -314
  -329
Prev. year cash balance distribution, $m
  90
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  209
  134
  148
  163
  179
  195
  212
  230
  248
  267
  282
  302
  323
  345
  368
  391
  416
  441
  468
  495
  524
  554
  585
  618
  652
  687
  725
  763
  804
  846
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  201
  122
  129
  134
  139
  142
  143
  143
  142
  140
  134
  129
  123
  116
  108
  99
  91
  81
  72
  63
  54
  46
  38
  31
  25
  20
  16
  12
  9
  6
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

ICU Medical, Inc. is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company's product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems. The primary critical care products it manufactures are Hemodynamic Monitoring Systems, SafeSet Closed Blood Sampling and Conservation System, Transpac Consumable Blood Pressure Transducers and Other Critical Care Products. The primary oncology products it manufactures are ChemoLock Needlefree CSTD, ChemoClave Needlefree CSTD and Diana Hazardous Drug Compounding System. As of December 31, 2016, its products were used in acute care hospitals and ambulatory clinics in more than 65 countries throughout the world.

FINANCIAL RATIOS  of  ICU Medical (ICUI)

Valuation Ratios
P/E Ratio 68.7
Price to Sales 11.4
Price to Book 6.6
Price to Tangible Book
Price to Cash Flow 48.1
Price to Free Cash Flow 66.5
Growth Rates
Sales Growth Rate 10.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 78.6%
Cap. Spend. - 3 Yr. Gr. Rate 4.6%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 9.5%
Ret/ On Assets - 3 Yr. Avg. 7.4%
Return On Total Capital 10.2%
Ret/ On T. Cap. - 3 Yr. Avg. 7.9%
Return On Equity 10.2%
Return On Equity - 3 Yr. Avg. 7.9%
Asset Turnover 0.6
Profitability Ratios
Gross Margin 53%
Gross Margin - 3 Yr. Avg. 51.6%
EBITDA Margin 27.4%
EBITDA Margin - 3 Yr. Avg. 24.1%
Operating Margin 22.2%
Oper. Margin - 3 Yr. Avg. 18.3%
Pre-Tax Margin 22.4%
Pre-Tax Margin - 3 Yr. Avg. 18.6%
Net Profit Margin 16.6%
Net Profit Margin - 3 Yr. Avg. 12.7%
Effective Tax Rate 25.9%
Eff/ Tax Rate - 3 Yr. Avg. 32.2%
Payout Ratio 0%

ICUI stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ICUI stock intrinsic value calculation we used $1292.613 million for the last fiscal year's total revenue generated by ICU Medical. The default revenue input number comes from 0001 income statement of ICU Medical. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ICUI stock valuation model: a) initial revenue growth rate of 8.7% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ICUI is calculated based on our internal credit rating of ICU Medical, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of ICU Medical.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ICUI stock the variable cost ratio is equal to 78.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for ICUI stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for ICU Medical.

Corporate tax rate of 27% is the nominal tax rate for ICU Medical. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ICUI stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ICUI are equal to 22.3%.

Life of production assets of 5 years is the average useful life of capital assets used in ICU Medical operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ICUI is equal to 27.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $1198.254 million for ICU Medical - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 20.468 million for ICU Medical is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of ICU Medical at the current share price and the inputted number of shares is $5.4 billion.

RELATED COMPANIES Price Int.Val. Rating
EW Edwards Lifesc 145.42 121.67  hold
MMSI Merit Medical 62.72 1.24  str.sell
BDX Becton Dickins 238.09 1,279.12  str.buy
ANGO AngioDynamics 20.14 9.05  str.sell
PFE Pfizer 44.50 34.10  hold
BAX Baxter Interna 69.46 13.73  str.sell
IRMD iRadimed 25.97 36.71  buy
TFX Teleflex 243.39 204.28  hold

COMPANY NEWS

▶ ICU Medical (ICUI) Enters Oversold Territory   [Sep-24-18 08:36AM  Zacks]
▶ Deals of the day-Mergers and acquisitions   [Sep-04-18 08:21AM  Reuters]
▶ PRESS DIGEST- British Business - Sept 4   [Sep-03-18 07:17PM  Reuters]
▶ ICU Medical: 2Q Earnings Snapshot   [05:07PM  Associated Press]
▶ ICU Medical, Inc. to Host Earnings Call   [02:30PM  ACCESSWIRE]
▶ Deals of the day-Mergers and acquisitions   [Aug-08-18 06:14AM  Reuters]
▶ [$$] Smiths Group: surgical intervention   [12:40AM  Financial Times]
▶ PRESS DIGEST- Financial Times - May 28   [May-27-18 08:05PM  Reuters]
▶ Is ICU Medical Incs (NASDAQ:ICUI) Liquidity Good Enough?   [May-17-18 08:51PM  Simply Wall St.]
▶ ICU Medical: 1Q Earnings Snapshot   [May-09-18 06:55PM  Associated Press]
▶ Edited Transcript of ICUI presentation 8-Mar-17 2:50pm GMT   [Apr-10-18 01:34PM  Thomson Reuters StreetEvents]
▶ Does ICU Medical Incs (NASDAQ:ICUI) PE Ratio Warrant A Sell?   [Mar-20-18 07:34PM  Simply Wall St.]
▶ ICU Medical posts 4Q profit   [Mar-01-18 07:10PM  Associated Press]
▶ ICU Medical, Inc. to Host Earnings Call   [12:00PM  ACCESSWIRE]
▶ Are ICU Medical Incs (NASDAQ:ICUI) Interest Costs Too High?   [Jan-03-18 03:08PM  Simply Wall St.]
▶ ETFs with exposure to ICU Medical, Inc. : January 1, 2018   [Jan-01-18 11:40AM  Capital Cube]
▶ Six Off the Beaten Path Healthcare Stock Gems   [Dec-09-17 12:00PM  TheStreet.com]
▶ ICU Medical posts 3Q profit   [Nov-09-17 06:27PM  Associated Press]
▶ ICU Medical, Inc. to Host Earnings Call   [12:00PM  ACCESSWIRE]
▶ 4 Medical Device Stocks to Top Q3 Earnings   [Nov-01-17 03:57PM  Zacks]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.